CTLA4 and neoplasm: Recent data have demonstrated that immunotherapies against immune checkpoints (e.g., CTLA-4 or PD-1) downregulate two main negative regulators of the anti-tumor immune response [93,115,116,117], resulting in durable anti-tumor responses in a subset of cancer patients, including those with melanoma [2,118].